Table 2. Stratification analysis for association between WTAP gene genotypes and neuroblastoma susceptibility.
| Variables | rs9457712 (case/control) | rs1853259 (case/control) | rs7766006 (case/control) | Risk genotypes (case/control) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GG | GA/AA | AOR (95% CI)a | Pa | AA | AG/GG | AOR (95% CI)a | Pa | GG | GT/TT | AOR (95% CI)a | Pa | 0 | 1–2 | AOR (95% CI)a | Pa | ||||
| Age, month | |||||||||||||||||||
| ≤18 | 218/482 | 126/231 | 1.21 (0.92–1.58) | 0.175 | 146/257 | 198/456 | 0.77 (0.59–0.998) | 0.048 | 123/234 | 221/479 | 0.88 (0.67–1.15) | 0.357 | 145/350 | 199/363 | 1.32 (1.02–1.71) | 0.036 | |||
| >18 | 383/685 | 169/334 | 0.91 (0.73–1.14) | 0.418 | 187/367 | 365/652 | 1.09 (0.88–1.36) | 0.431 | 181/350 | 371/669 | 1.07 (0.86–1.33) | 0.554 | 284/500 | 268/519 | 0.92 (0.75–1.13) | 0.411 | |||
| Gender | |||||||||||||||||||
| Female | 275/510 | 131/234 | 1.04 (0.80–1.35) | 0.786 | 143/260 | 263/484 | 0.98 (0.76–1.26) | 0.879 | 139/238 | 267/506 | 0.92 (0.71–1.19) | 0.522 | 200/378 | 206/366 | 1.07 (0.84–1.36) | 0.613 | |||
| Male | 326/657 | 164/331 | 1.00 (0.79–1.26) | 0.985 | 190/364 | 300/624 | 0.92 (0.73–1.15) | 0.439 | 165/346 | 325/642 | 1.06 (0.84–1.33) | 0.614 | 229/472 | 261/516 | 1.05 (0.84–1.30) | 0.689 | |||
| Sites of origin | |||||||||||||||||||
| Adrenal gland | 165/1,167 | 83/565 | 1.03 (0.78–1.37) | 0.826 | 89/624 | 159/1,108 | 1.01 (0.76–1.33) | 0.963 | 92/584 | 156/1,148 | 0.88 (0.67–1.16) | 0.353 | 122/850 | 126/882 | 0.99 (0.76–1.30) | 0.954 | |||
| Retroperitoneal | 219/1,167 | 99/565 | 0.93 (0.72–1.20) | 0.559 | 118/624 | 200/1,108 | 0.95 (0.74–1.22) | 0.678 | 101/584 | 217/1,148 | 1.11 (0.86–1.44) | 0.419 | 155/850 | 163/882 | 1.01 (0.79–1.28) | 0.938 | |||
| Mediastinum | 138/1,167 | 75/565 | 1.14 (0.84–1.53) | 0.406 | 80/624 | 133/1,108 | 0.93 (0.69–1.24) | 0.610 | 68/584 | 145/1,148 | 1.07 (0.79–1.45) | 0.664 | 98/850 | 115/882 | 1.15 (0.86–1.53) | 0.348 | |||
| Others | 72/1,167 | 33/565 | 0.95 (0.62–1.46) | 0.825 | 42/624 | 63/1,108 | 0.84 (0.56–1.26) | 0.395 | 38/584 | 67/1,148 | 0.89 (0.59–1.34) | 0.560 | 49/850 | 56/882 | 1.11 (0.75–1.65) | 0.605 | |||
| Clinical stage | |||||||||||||||||||
| I + II +4 s | 317/1,167 | 152/565 | 1.00 (0.80–1.24) | 0.972 | 176/624 | 293/1,108 | 0.94 (0.76–1.16) | 0.553 | 162/584 | 307/1,148 | 0.96 (0.77–1.19) | 0.678 | 229/850 | 240/882 | 1.02 (0.83–1.25) | 0.889 | |||
| III + IV | 265/1,167 | 129/565 | 1.01 (0.80–1.28) | 0.944 | 142/624 | 252/1,108 | 0.99 (0.78–1.24) | 0.903 | 131/584 | 263/1,148 | 1.03 (0.81–1.30) | 0.809 | 187/850 | 207/882 | 1.08 (0.86–1.35) | 0.504 | |||
a, adjusted for age and gender, omitting the corresponding stratify factor. AOR, adjusted odds ratio; CI, confidence interval.